At the same time, DFS analysis was performed on 982 patients with early stage NSCLC, and the FOXP3 could be used as an indicator of DFS prediction (HR: 1.88, P = 1.1E−10), in Fig. 3B. Here, FOXP3 is linked to non-small cell lung carcinoma.